Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jabil Inc (JBL) vs GeneDx Holdings Corp (WGS) Price & Performance

Jabil IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Jabil Inc vs GeneDx Holdings Corp — how do they compare? Jabil Inc trades at $316.4 (market cap $32.06B), while GeneDx Holdings Corp trades at $60.64 (market cap $1.80B). The key difference: Jabil Inc is far larger — about 17.8× GeneDx Holdings Corp's market cap, and Jabil Inc pays a 0.1% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

JBLWGS
Market Cap
$32.06B$1.80B
Sector
TechnologyTechnology
52-Week High
$385.50$167.51
52-Week Low
$192.49$34.51
Enterprise Value
$34.59B$1.80B
Dividend Yield
0.1%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jabil Inc

JBL trades at $305.91, up 1.63% today but down significantly from recent highs, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamental performance with consistent earnings beats, 20.62% ROE, and robust revenue growth projections to $33.6B for 2026. Recent developments include expansion of AI infrastructure capabilities and new logistics facilities.

JBL presents a compelling growth story driven by AI infrastructure demand, with analysts maintaining strong buy ratings and a $448.29 consensus target representing 46% upside. However, elevated P/E ratio of 37.67 and competitive pressures in electronics manufacturing warrant caution. The stock's recent pullback may offer entry opportunity for long-term investors bullish on AI-driven growth.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.

Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.

Returns comparison

Trailing returns across standard periods

About Jabil Inc

Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.

Read more on JBL

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS